Subcutaneous amivantamab is safer and more convenient for patients compared with the intravenous formulation, according to Misako Nagasaka, MD, PhD.
|Poll|July 7, 2016
Subpleural Mass in 46-Year-Old Patient
Author(s)Cesar A. Moran, MD
A 46-year-old man presents with a cough and chest pain. Chest imaging shows a subpleural mass in his left upper lobe, and a biopsy is performed. What is your diagnosis?
Advertisement
Advertisement
Related to this article
Mary Jo Lechowicz, MD, discussed how pre-transplant depth of response informs the choice between autologous and allogeneic HSCT in T-cell lymphoma.
Jasmine Zain, MD, described the molecular workup to determine whether a secondary malignancy after CAR T-cell therapy reflects direct insertional mutagenesis.
SOHO 2026 sessions covered chemoimmunotherapy in frontline DLBCL, treatment selection via molecular classifiers, and bispecific antibodies for unfit patients.
The FDA cleared the Triton 1 robotic endoscopy system for diagnostic and therapeutic procedures such as colorectal cancer screening and lesion removal.
ASTRO’s first standalone clinical practice guideline for bladder cancer recommends trimodal therapy vs radical cystectomy for select muscle-invasive disease cases.
Investigators are evaluating cesalatamig among patients with advanced cancer in the international phase 1/2 BiPAVE-001 trial.
The FDA granted fast track designation to the oral pan-KRAS inhibitor KST-6051 for patients with KRAS-mutant advanced or metastatic solid tumors.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves sNDA for Taletrectinib in TKI-Naive Advanced ROS1+ NSCLC
2
FDA Clears Triton Robotic Endoscopy System for Colon Procedures
3
ASTRO Issues First Clinical Practice Guideline on Radiation for Bladder Cancer
4
KST-6051 Receives FDA Fast Track Designation in KRAS-Mutant Solid Tumors
5